New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop-Reference-Cited by-同舟云学术

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

Published:2024-01 Issue:1 Volume:10 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Telpoukhovskaia Maria A.¹^ORCID,Murdy Thomas J.¹,Marola Olivia J.¹,Charland Kevin¹,MacLean Michael¹,Luquez Tain²,Lish Alexandra M.³,Neuner Sarah⁴,Dunn Amy¹,Onos Kristen D.¹,Wiley Jesse⁵,Archer Derek⁶⁷⁸,Huentelman Matthew J.⁹,Arnold Matthias¹⁰¹¹,Menon Vilas²,Goate Alison⁴,Van Eldik Linda J.¹²,Territo Paul R.¹³¹⁴,Howell Gareth R.¹¹⁵¹⁶¹⁷,Carter Gregory W.¹¹⁵¹⁶¹⁷,O'Connell Kristen M. S.¹¹⁵¹⁶¹⁷,Kaczorowski Catherine C.¹¹⁸,

Affiliation:

1. The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA

2. Center for Translational and Computational Neuroimmunology Department of Neurology Columbia University Irving Medical Center New York New York USA

3. Ann Romney Center for Neurologic Diseases Department of Neurology Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

4. Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA

5. Sage Bionetworks Seattle Washington USA

6. Vanderbilt Memory and Alzheimer's Center Vanderbilt University Medical Center Nashville Tennessee USA

7. Department of Neurology Vanderbilt University Medical Center Nashville Tennessee USA

8. Vanderbilt Genetics Institute Vanderbilt University School of Medicine Nashville Tennessee USA

9. Neurogenomics Division Translational Genomics Research Institute (TGen) Phoenix Arizona USA

10. Institute of Computational Biology Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg Germany

11. Department of Psychiatry and Behavioral Sciences Duke University Durham North Carolina USA

12. Sanders‐Brown Center on Aging University of Kentucky Lexington Kentucky USA

13. Department of Medicine Division of Clinical Pharmacology Indiana University School of Medicine Indianapolis Indiana USA

14. Stark Neuroscience Research Institute Indiana University School of Medicine Indianapolis Indiana USA

15. Graduate School of Biomedical Science and Engineering University of Maine Orono Maine USA

16. Neuroscience Program, Graduate School of Biomedical Science Tufts University School of Medicine Boston Massachusetts USA

17. Genetics Program, Graduate School of Biomedical Science Tufts University School of Medicine Boston Massachusetts USA

18. Department of Neurology University of Michigan Ann Arbor Michigan USA

Abstract

AbstractINTRODUCTIONIn September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field.METHODSDuring the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic.RESULTSThe team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de‐risk clinical pipeline, and (4) centralize data management.DISCUSSIONIn this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.

Funder

Alzheimer's Association

National Institute on Aging

National Center for Advancing Translational Sciences

National Institute on Drug Abuse

National Cancer Institute

National Eye Institute

Publisher

Wiley

Reference61 articles.

1. Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

2. Lecanemab in Early Alzheimer’s Disease

3. Natural genetic variation determines microglia heterogeneity in wild-derived mouse models of Alzheimer’s disease

4. Neurotoxic reactive astrocytes are induced by activated microglia

5. Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review